FDA-approved EGFR/ErbB1 inhibitors such as afatinib, dacomitinib, erlotinib, gefitinib, and osimertinib have been developed for the treatment of non-small cell lung cancer (NSCLC). Here, EGFR is linked to non-small cell lung carcinoma.